微调 T 细胞疗法的效果。
Fine-tuning the effects of T-cell therapy.
出版信息
Cancer Discov. 2014 Feb;4(2):137. doi: 10.1158/2159-8290.CD-NB2013-184. Epub 2014 Jan 9.
Abstract
Researchers have engineered molecules called inhibitory chimeric antigen receptors that can help divert off-target responses, better protecting normal tissues from damage caused by some engineered T-cell therapies.
摘要
研究人员设计了一种名为抑制性嵌合抗原受体的分子，它可以帮助转移非靶向反应，更好地保护正常组织免受一些工程 T 细胞疗法引起的损伤。
相似文献
1
Fine-tuning the effects of T-cell therapy.微调 T 细胞疗法的效果。
Cancer Discov. 2014 Feb;4(2):137. doi: 10.1158/2159-8290.CD-NB2013-184. Epub 2014 Jan 9.
2
Chimeric antigen receptor T cell therapy: 25years in the making.嵌合抗原受体T细胞疗法：历经25年研发而成。
Blood Rev. 2016 May;30(3):157-67. doi: 10.1016/j.blre.2015.10.003. Epub 2015 Nov 6.
3
T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition.基于 T 细胞的免疫疗法：过继细胞转移和检查点抑制。
Cancer Immunol Res. 2015 Oct;3(10):1115-22. doi: 10.1158/2326-6066.CIR-15-0190.
4
Cancer-killing CAR therapies gain speed.抗癌嵌合抗原受体疗法提速。
Cancer Discov. 2015 Jan;5(1):7. doi: 10.1158/2159-8290.CD-ND2014-013. Epub 2015 Jan 5.
5
Of chimeric antigen receptors and antibodies: OX40 and 41BB costimulation sharpen up T cell-based immunotherapy of cancer.关于嵌合抗原受体和抗体：OX40和4-1BB共刺激增强了基于T细胞的癌症免疫疗法。
Immunotherapy. 2013 Jul;5(7):677-81. doi: 10.2217/imt.13.54.
6
Helping CAR T cells reach tumors.帮助 CAR T 细胞到达肿瘤。
Cancer Discov. 2015 Jan;5(1):OF6. doi: 10.1158/2159-8290.CD-NB2014-173. Epub 2014 Nov 26.
7
Moving receptor redirected adoptive cell therapy toward fine tuning of antitumor responses.将移动受体重定向过继性细胞疗法用于精准调节抗肿瘤反应。
Int Rev Immunol. 2014 Oct;33(5):402-16. doi: 10.3109/08830185.2014.917412. Epub 2014 Jun 9.
8
Improving the efficacy and safety of engineered T cell therapy for cancer.提高工程化 T 细胞疗法治疗癌症的疗效和安全性。
Cancer Lett. 2013 Jan 28;328(2):191-7. doi: 10.1016/j.canlet.2012.09.015. Epub 2012 Sep 27.
9
Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future.用于癌症过继性免疫治疗的嵌合T细胞：利用所学知识规划未来
Immunotherapy. 2009 Nov;1(6):905-12. doi: 10.2217/imt.09.69.
10
First Chimeric Antigen Receptor T-Cell Therapy Approved.首个嵌合抗原受体T细胞疗法获批。
J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx251.
Zotero 插件